Medical
-
The Bill and Melinda Gates Foundation has awarded a $2.5 million grant to researchers at Liverpool School of Tropical Medicine (LSTM) for a study to determine the effects of nasal spray flu vaccine on pneumococcal… Read more . . .
-
The Australian Research Council has awarded a $521,800 grant to Daniela Traini and Paul Young of the Woolcock Institute’s RespiTech group and Patrick Spicer of the University of New South Wales for development of inhalable… Read more . . .
-
Avanir Pharmaceuticals has published results from the Phase 3 TARGET study of its AVP-825 intranasal sumatriptan powder compared to placebo for the treatment of migraine. The article appears in the January 2015 issue of Headache.… Read more . . .
-
US-based Monaghan Medical, which sells breath actuated nebulizers manufactured by Trudell Medical International (TMI), is presenting data at CHEST 2014 from a study showing that continuous nebulizers may under-dose medication. According to Monaghan changes in… Read more . . .
-
Sunovion Pharmaceuticals has announced that all 4 dose levels of its SUN-101 glycopyrrolate inhalation solution tested in a Phase 2 study produced statistically significant improvements in lung function. The 28-day randomized, double-blind, placebo-controlled study involved… Read more . . .
-
Data from Boehringer Ingelheims ANHELTO 1 and ANHELTO 2 studies demonstrate that co-administration of the Spiriva HandiHaler tiotropium DPI and the Striverdi Respimat olodaterol SMI produced significantly greater improvement in the lung function of COPD… Read more . . .
-
Results from a 24-week study comparing GSK’s Anoro Ellipta umeclidinium /vilanterol DPI to Boehringer Ingelheim’s Spiriva Handihaler tiotropium DPI published in Respiratory Medicine show statistically greater improvement in trough FEV1 and weighted mean FEV1 0… Read more . . .
-
California-based biopharmaceutical company OrPro Therapeutics says that pre-clinical studies of its lead compound, ORP-100, an inhaled thioredoxin, has shown that ORP-100 reduces the viscosity and adhesiveness of the sputum of cystic fibrosis patients both in… Read more . . .
-
Savara Pharmaceuticals has announced the completion of enrollment in a Phase 2 trial of its AeroVanc vancomycin DPI for the treatment of for the treatment of methicillin-resistant S. aureus (MRSA) lung infections in cystic fibrosis… Read more . . .
-
Verona Pharma says that the company will present data at the upcoming North American Cystic Fibrosis Conference showing that its RPL554 inhaled PDE3/PDE4 inhibitor could be useful in treating CF. According to the company, “The… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland